KRAS and non-small cell lung carcinoma: Two cell lines were established from patients with BRAF class 3–mutated NSCLC, and their sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs) was assessed using EGFR-mutated, BRAF class 1 and 2–mutated, and KRAS-mutated NSCLC cell lines as controls.